Tagged with

Switzerland With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try and further dialogue between pharmaceutical companies, regulators, healthcare professionals and patients on the issue of expanding access to medicines. At…

Poland Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the…

Lithuania Marius Giedraitis, director and founder of Balux, explains the company’s commitment to shipping high-value temperature-sensitive pharmaceuticals with quality goals of 99.5 percent of deliveries without any deviation by 2019. Could you please introduce the main activities and operations of Balux to our international audience? “Our niche strategy helps us to…

Serbia Silvana Džudžević, managing director of Serbia’s leading pharma wholesale and distribution specialist, Farmalogist, introduces the evolution of the company’s operations to now include several complementary services, its numerous partnerships with international MNCs, and its utilization of digital solutions to cement the company as the partner of choice moving forward. Could…

Poland Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments. Furthermore, he highlights the company’s international strategy and strong manufacturing capabilities, both for their own treatments and in the context…

Switzerland Cristina Marti’s colorful and successful career has taken her across Asia from Spain, before settling in Switzerland with Indukern. In this interview, Marti explores themes of competition in Switzerland, the differences in global markets and why Indukern Switzerland and other API sourcing firms are a reliable route to understanding market…

Serbia Marija Krstic, general manager of GSK Serbia and Montenegro, discusses how the various positions she has undertaken during her 13-year career at GSK help inform her current role, the initiatives that GSK Serbia is involved in to increase access to innovative medicines for Serbian patients, and her push to ensure…

Brazil Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past, present, and future challenges of this pioneering medical device company that started in 1985. In this interview, Dr. Balestrassi –…

Switzerland Karen Huebscher, CEO of Solvias, a Swiss-headquartered world leader in contract research, development and manufacturing, explains her decision to join the company after a distinguished career at Novartis, the evolution of pharmaceutical client demands, and Solvias’s evolving international footprint. After more than 15 years with Switzerland’s largest life sciences group…

Serbia Predrag Bogavac, now Country Head, OGM Serbia and Montenegro, a.i. Oncology General Manager Bulgaria and Macedonia at Novartis, shares the highlights of the past two years as Country Head of Novartis Serbia and Montenegro, his responsibilities as Head of Oncology, the challenges within the Serbian market, particularly surrounding reimbursement, and…

Brazil Paulo Vitor de Andrade, founder and director of Grupo Polar, elaborates on his journey to build the Brazilian company of reference in cold chain solutions and the company’s relentless efforts to disseminate knowledge to improve the logistics environment in Brazil and globally. Grupo Polar is recognized as a reference in…

Brazil Poul Sorensen, director of Geistlich Pharma in Brazil, details the importance of educational activities for Geistlich’s business, the affiliate’s desire to bring new segments of Geistlich’s portfolio to Brazil and the necessity of adapting the business strategy to each region in Brazil according to their price sensitivity. Could you introduce…